Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2Sharad K Verma, Xinrong Tian, Louis V LaFrance, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic MalignanciesMark A Dawson, Gautam Borthakur, Brian J P Huntly, et al.
Cancer Cell|October 1, 2019
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerMarian L Burr, Christina E Sparbier, Kah Lok Chan, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Cancer Cell|May 18, 2013
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformationWendy Béguelin, Relja Popovic, Matt Teater, et al.
Science Translational Medicine|February 24, 2017
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2Lian Dee Ler, Sujoy Ghosh, Xiaoran Chai, et al.
Cancer Cell|July 16, 2015
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLCHelai P Mohammad, Kimberly N Smitheman, Chandrashekhar D Kamat, et al.
Nature Chemical Biology|October 6, 2015
New IDH1 mutant inhibitors for treatment of acute myeloid leukemiaUjunwa C Okoye-Okafor, Boris Bartholdy, Jessy Cartier, et al.
Cancer Cell|July 2, 2019
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossAndrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, et al.
Nature Cancer|November 18, 2021
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemiaMelissa B Pappalardi, Kathryn Keenan, Mark Cockerill, et al.
Pageof 5